EP Patent

EP1734040A4 — SUBSTITUTED QUINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE

Assigned to MSD KK · Expires 2007-11-28 · 18y expired

What this patent protects

A compound having the activity of glucokinase activation and being useful for the prevention or treatment of diabetes, etc., represented by the formula: (I) [wherein X is a nitrogen atom, etc.; Y is an oxygen atom, etc.; R1 is an optionally substituted 5 to 6-membered heteroaryl …

USPTO Abstract

A compound having the activity of glucokinase activation and being useful for the prevention or treatment of diabetes, etc., represented by the formula: (I) [wherein X is a nitrogen atom, etc.; Y is an oxygen atom, etc.; R1 is an optionally substituted 5 to 6-membered heteroaryl group, etc.; R2 is a hydrogen atom or a fluorine atom; and the ring A is an optionally substituted monocyclic or bicyclic heteroaryl group of the formula: (II) ], or a pharmacologically acceptable salt thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP1734040A4
Jurisdiction
EP
Classification
—
Expires
2007-11-28
Drug substance claim
No
Drug product claim
No
Assignee
MSD KK
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.